 Jacquelyn Bainbridge
Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anticonvulsants | 6 | 2020 | 246 | 1.450 |
Why?
| | Parkinson Disease | 11 | 2024 | 601 | 1.050 |
Why?
| | Seizures | 5 | 2017 | 485 | 0.630 |
Why?
| | Multiple Sclerosis | 2 | 2016 | 489 | 0.570 |
Why?
| | Drug Resistant Epilepsy | 1 | 2020 | 140 | 0.540 |
Why?
| | Education, Pharmacy | 2 | 2017 | 120 | 0.510 |
Why?
| | Pharmacy | 1 | 2017 | 32 | 0.500 |
Why?
| | Quality of Life | 3 | 2020 | 3211 | 0.480 |
Why?
| | Neurology | 1 | 2017 | 117 | 0.460 |
Why?
| | Psychotropic Drugs | 1 | 2016 | 78 | 0.460 |
Why?
| | Antiparkinson Agents | 3 | 2017 | 41 | 0.440 |
Why?
| | Laboratory Proficiency Testing | 1 | 2014 | 9 | 0.420 |
Why?
| | Disability Evaluation | 1 | 2016 | 311 | 0.420 |
Why?
| | Monitoring, Immunologic | 1 | 2014 | 25 | 0.420 |
Why?
| | CD3 Complex | 1 | 2014 | 112 | 0.400 |
Why?
| | CD4 Lymphocyte Count | 1 | 2014 | 280 | 0.400 |
Why?
| | Laboratories | 1 | 2014 | 110 | 0.390 |
Why?
| | Creatine | 4 | 2017 | 63 | 0.390 |
Why?
| | Epilepsy | 4 | 2020 | 390 | 0.390 |
Why?
| | Immunophenotyping | 1 | 2014 | 322 | 0.380 |
Why?
| | 4-Aminopyridine | 1 | 2012 | 30 | 0.370 |
Why?
| | Potassium Channel Blockers | 1 | 2012 | 47 | 0.370 |
Why?
| | Gait Disorders, Neurologic | 1 | 2012 | 44 | 0.360 |
Why?
| | Immunotherapy | 1 | 2016 | 668 | 0.330 |
Why?
| | Cannabidiol | 2 | 2024 | 142 | 0.330 |
Why?
| | Dronabinol | 3 | 2024 | 249 | 0.330 |
Why?
| | Drug Interactions | 5 | 2016 | 405 | 0.310 |
Why?
| | Piracetam | 1 | 2009 | 14 | 0.300 |
Why?
| | Gait | 1 | 2012 | 312 | 0.300 |
Why?
| | Fructose | 2 | 2008 | 132 | 0.290 |
Why?
| | Restless Legs Syndrome | 3 | 2016 | 20 | 0.290 |
Why?
| | Clinical Trials as Topic | 1 | 2014 | 1062 | 0.290 |
Why?
| | Monoamine Oxidase Inhibitors | 1 | 2008 | 20 | 0.280 |
Why?
| | Monoamine Oxidase | 1 | 2008 | 27 | 0.280 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2014 | 923 | 0.270 |
Why?
| | Walking | 1 | 2012 | 545 | 0.260 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2014 | 1146 | 0.260 |
Why?
| | Epistaxis | 1 | 2006 | 17 | 0.240 |
Why?
| | Caffeine | 2 | 2017 | 74 | 0.230 |
Why?
| | Abdominal Neoplasms | 1 | 2025 | 47 | 0.230 |
Why?
| | Cannabinoids | 2 | 2025 | 184 | 0.220 |
Why?
| | Diabetic Neuropathies | 1 | 2006 | 100 | 0.220 |
Why?
| | Patient Compliance | 1 | 2009 | 588 | 0.210 |
Why?
| | Depression | 3 | 2009 | 1559 | 0.190 |
Why?
| | Disease Progression | 4 | 2017 | 2865 | 0.170 |
Why?
| | Pain | 1 | 2006 | 791 | 0.160 |
Why?
| | Humans | 31 | 2025 | 145783 | 0.160 |
Why?
| | Volatilization | 1 | 2019 | 45 | 0.150 |
Why?
| | Nebulizers and Vaporizers | 1 | 2019 | 62 | 0.150 |
Why?
| | Dopamine Agonists | 2 | 2016 | 41 | 0.150 |
Why?
| | Ketosis | 1 | 1999 | 12 | 0.150 |
Why?
| | Starvation | 1 | 1999 | 23 | 0.150 |
Why?
| | Cannabis | 2 | 2023 | 510 | 0.140 |
Why?
| | Pharmaceutical Services | 1 | 1999 | 76 | 0.140 |
Why?
| | HIV Infections | 1 | 2014 | 3195 | 0.140 |
Why?
| | Comorbidity | 2 | 2016 | 1662 | 0.130 |
Why?
| | Dibenzazepines | 1 | 2017 | 5 | 0.130 |
Why?
| | Severity of Illness Index | 5 | 2017 | 2933 | 0.130 |
Why?
| | Schools, Pharmacy | 1 | 2017 | 48 | 0.130 |
Why?
| | Practice Guidelines as Topic | 2 | 2016 | 1582 | 0.120 |
Why?
| | Double-Blind Method | 5 | 2024 | 2064 | 0.120 |
Why?
| | Analgesics, Opioid | 1 | 2025 | 1154 | 0.120 |
Why?
| | Metabolic Diseases | 1 | 2017 | 114 | 0.120 |
Why?
| | Air Pollution | 1 | 2019 | 315 | 0.120 |
Why?
| | Female | 19 | 2025 | 79045 | 0.120 |
Why?
| | Teratogens | 1 | 2015 | 25 | 0.110 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2015 | 30 | 0.110 |
Why?
| | Drug Synergism | 1 | 2016 | 354 | 0.110 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2017 | 229 | 0.110 |
Why?
| | Cognition | 1 | 2023 | 1271 | 0.110 |
Why?
| | Psychiatry | 1 | 2017 | 195 | 0.100 |
Why?
| | Pharmacists | 1 | 2017 | 258 | 0.100 |
Why?
| | Male | 15 | 2025 | 73010 | 0.100 |
Why?
| | Monitoring, Physiologic | 1 | 2016 | 289 | 0.100 |
Why?
| | Treatment Outcome | 4 | 2024 | 11794 | 0.100 |
Why?
| | Quality Control | 1 | 2014 | 161 | 0.100 |
Why?
| | Electrocardiography | 1 | 2017 | 668 | 0.100 |
Why?
| | Lactation | 1 | 2014 | 193 | 0.100 |
Why?
| | Observer Variation | 1 | 2014 | 357 | 0.100 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1271 | 0.100 |
Why?
| | Computer Simulation | 1 | 2017 | 1003 | 0.090 |
Why?
| | Prognosis | 2 | 2025 | 4330 | 0.090 |
Why?
| | Heart Rate | 1 | 2017 | 856 | 0.090 |
Why?
| | Aged | 10 | 2025 | 26217 | 0.090 |
Why?
| | Postoperative Complications | 1 | 2025 | 2977 | 0.090 |
Why?
| | Workflow | 1 | 2014 | 183 | 0.090 |
Why?
| | Physical Therapy Modalities | 1 | 2016 | 337 | 0.090 |
Why?
| | Specimen Handling | 1 | 2014 | 183 | 0.090 |
Why?
| | Data Interpretation, Statistical | 1 | 2014 | 368 | 0.090 |
Why?
| | Program Development | 1 | 2014 | 368 | 0.090 |
Why?
| | Middle Aged | 13 | 2025 | 36309 | 0.090 |
Why?
| | Quality Indicators, Health Care | 1 | 2014 | 336 | 0.090 |
Why?
| | Drug Costs | 1 | 2012 | 117 | 0.080 |
Why?
| | Follow-Up Studies | 3 | 2025 | 5428 | 0.080 |
Why?
| | Purines | 1 | 2012 | 187 | 0.080 |
Why?
| | Aged, 80 and over | 4 | 2015 | 8347 | 0.080 |
Why?
| | Flow Cytometry | 1 | 2014 | 1165 | 0.080 |
Why?
| | Curriculum | 1 | 2017 | 1074 | 0.080 |
Why?
| | Models, Statistical | 1 | 2014 | 672 | 0.080 |
Why?
| | Program Evaluation | 1 | 2014 | 944 | 0.080 |
Why?
| | Guideline Adherence | 1 | 2014 | 587 | 0.080 |
Why?
| | Pregnancy Complications | 1 | 2014 | 603 | 0.070 |
Why?
| | Epilepsies, Partial | 1 | 2009 | 63 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2014 | 2123 | 0.070 |
Why?
| | Reproducibility of Results | 2 | 2014 | 3418 | 0.070 |
Why?
| | Patient Selection | 1 | 2012 | 739 | 0.070 |
Why?
| | Recovery of Function | 1 | 2012 | 716 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 1 | 2017 | 2399 | 0.070 |
Why?
| | Pyrazoles | 1 | 2012 | 517 | 0.070 |
Why?
| | Citalopram | 1 | 2008 | 32 | 0.070 |
Why?
| | Polypharmacy | 1 | 2009 | 94 | 0.070 |
Why?
| | Memory Disorders | 1 | 2009 | 197 | 0.060 |
Why?
| | Health Services | 1 | 2008 | 113 | 0.060 |
Why?
| | Mental Disorders | 1 | 2016 | 1171 | 0.060 |
Why?
| | Time Factors | 2 | 2017 | 7134 | 0.060 |
Why?
| | Community Pharmacy Services | 1 | 2007 | 46 | 0.060 |
Why?
| | Accreditation | 1 | 2007 | 101 | 0.060 |
Why?
| | Adult | 8 | 2025 | 40881 | 0.060 |
Why?
| | Risk Assessment | 1 | 2016 | 3752 | 0.060 |
Why?
| | Pharmacy Service, Hospital | 1 | 2007 | 89 | 0.060 |
Why?
| | Data Collection | 1 | 2008 | 643 | 0.060 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 1043 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2009 | 426 | 0.060 |
Why?
| | Quality Improvement | 1 | 2014 | 1296 | 0.060 |
Why?
| | Longitudinal Studies | 3 | 2017 | 2968 | 0.060 |
Why?
| | Neoplasms | 1 | 2020 | 2913 | 0.050 |
Why?
| | Physician-Patient Relations | 1 | 2009 | 588 | 0.050 |
Why?
| | Patient Education as Topic | 1 | 2009 | 777 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2017 | 2028 | 0.050 |
Why?
| | Chronic Disease | 1 | 2009 | 1812 | 0.050 |
Why?
| | Biomarkers | 1 | 2014 | 4302 | 0.050 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 782 | 0.040 |
Why?
| | 2-Propanol | 1 | 2019 | 20 | 0.040 |
Why?
| | Limit of Detection | 1 | 2019 | 92 | 0.040 |
Why?
| | Food-Drug Interactions | 1 | 1999 | 11 | 0.040 |
Why?
| | Diet, Protein-Restricted | 1 | 1999 | 11 | 0.040 |
Why?
| | Calibration | 1 | 2019 | 152 | 0.040 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2019 | 174 | 0.040 |
Why?
| | Clinical Competence | 1 | 2007 | 1247 | 0.040 |
Why?
| | Surface Properties | 1 | 2019 | 386 | 0.030 |
Why?
| | Dietary Carbohydrates | 1 | 1999 | 147 | 0.030 |
Why?
| | Risk Factors | 1 | 2012 | 10919 | 0.030 |
Why?
| | Catechol O-Methyltransferase Inhibitors | 1 | 1997 | 6 | 0.030 |
Why?
| | Environmental Monitoring | 1 | 2019 | 347 | 0.030 |
Why?
| | Dietary Fats | 1 | 1999 | 308 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2017 | 196 | 0.030 |
Why?
| | Autonomic Nervous System | 1 | 2017 | 83 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2019 | 572 | 0.030 |
Why?
| | Marijuana Smoking | 1 | 2019 | 249 | 0.030 |
Why?
| | Gene-Environment Interaction | 1 | 2017 | 180 | 0.030 |
Why?
| | Women | 1 | 2015 | 47 | 0.030 |
Why?
| | Hemodiafiltration | 1 | 1995 | 7 | 0.030 |
Why?
| | Ciprofloxacin | 1 | 1995 | 31 | 0.030 |
Why?
| | Prospective Studies | 2 | 2025 | 8078 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 1997 | 821 | 0.030 |
Why?
| | Consensus | 1 | 2016 | 479 | 0.020 |
Why?
| | Central Nervous System Stimulants | 1 | 2015 | 185 | 0.020 |
Why?
| | Adenosine A2 Receptor Antagonists | 1 | 2012 | 14 | 0.020 |
Why?
| | Counseling | 1 | 2015 | 401 | 0.020 |
Why?
| | Palliative Care | 1 | 2020 | 1022 | 0.020 |
Why?
| | Pregnancy | 2 | 2015 | 7216 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 2012 | 116 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 740 | 0.020 |
Why?
| | Genotype | 1 | 2017 | 1857 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1512 | 0.020 |
Why?
| | Vasodilator Agents | 1 | 2012 | 330 | 0.020 |
Why?
| | Animals | 1 | 2012 | 38101 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2015 | 789 | 0.020 |
Why?
| | Age Factors | 1 | 2017 | 3346 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 2181 | 0.020 |
Why?
| | Exercise Test | 1 | 2012 | 630 | 0.020 |
Why?
| | Periodicity | 1 | 2008 | 58 | 0.020 |
Why?
| | Headache | 1 | 2008 | 151 | 0.020 |
Why?
| | Recurrence | 1 | 2008 | 1139 | 0.010 |
Why?
| | Pilot Projects | 1 | 2008 | 1898 | 0.010 |
Why?
| | Young Adult | 1 | 2015 | 14254 | 0.010 |
Why?
| | Ergolines | 1 | 1997 | 3 | 0.010 |
Why?
| | Catechols | 1 | 1997 | 14 | 0.010 |
Why?
| | Benzophenones | 1 | 1997 | 15 | 0.010 |
Why?
| | Nitrophenols | 1 | 1997 | 30 | 0.010 |
Why?
| | Benzothiazoles | 1 | 1997 | 39 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2015 | 17330 | 0.010 |
Why?
| | Colorado | 1 | 2007 | 4556 | 0.010 |
Why?
| | Thiazoles | 1 | 1997 | 142 | 0.010 |
Why?
| | Receptors, Dopamine D2 | 1 | 1997 | 93 | 0.010 |
Why?
| | Nitriles | 1 | 1997 | 211 | 0.010 |
Why?
| | Adolescent | 1 | 2015 | 22577 | 0.010 |
Why?
| | Liver Failure | 1 | 1995 | 83 | 0.010 |
Why?
| | Indoles | 1 | 1997 | 507 | 0.010 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1995 | 592 | 0.010 |
Why?
| | Critical Illness | 1 | 1995 | 900 | 0.000 |
Why?
| | Acute Kidney Injury | 1 | 1995 | 874 | 0.000 |
Why?
|
|
Bainbridge's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|